Eight days left on the HHS peptide docket. Late comments are not accepted; A biofilm-derived peptide that glues wet surfaces under water. Updated daily.
The Federal Register notice for HHS's enforcement-discretion policy on 503A compounding with certain peptide bulk drug substances (FR Doc. 2026-22192, published 30 October 2026) says written comments may be filed until two weeks after publication on docket HHS-OASH-2026-0496. That window closes on 13 November 2026. A regulations.gov refresh on the evening of 5 November 2026 still showed 12 posted comments, the docket still open for comment, and late comments not allowed. The same notice states the policy creates no rights for any person and is not binding on HHS or the public. It is a notice of availability, not an FDA approval of any compounded product. Our FDA Peptide Compounding Policy Tracker follows each step.
Science Advances reports a peptide derived from bacterial biofilms that adsorbs onto various surfaces and can glue wet surfaces under water. The authors characterised adsorption and adhesion with confocal microscopy, molecular dynamics simulations, atomic force microscopy, lap shear tests and spectroscopy, and also showed the peptide can coaggregate with microspheres as a flocculant. The work proposes bacterial biofilms as a design source for underwater adhesives, alongside the better-known marine-animal models. These are materials-science results only.
Eight AI peptide sequencing models, one shared blind spot: missing fragment ions
Photo: Image: BioLabs Research
A benchmark published in Nature Methods on 3 November 2026 compared eight deep-learning models that read peptide sequences straight from mass spectra, without a sequence database, on three public proteomics datasets. Performance varied between models, but many correct identifications overlapped. Post-processing steps such as iterative refinement, rescoring and reranking gave no or only modest gains. Most errors were the same across models and traced to limited fragment-ion coverage, the gaps in a spectrum where no fragment shows which residue comes next; the authors saw the same limit in database searches with large search spaces. Look-alike residue pairs of equal mass, such as leucine and isoleucine, remain hard to tell apart. These are analytical method results only.
FDA reviewers said no to all six peptides. HHS cites lab certificates that are not public yet
Photo: Image: BioLabs Research
Appendix B of the HHS 503A peptide policy, published in the Federal Register on 30 October 2026 (FR Doc. 2026-22192), says the FDA's drug center, CDER, recommended against listing each of the six peptides. HHS gives three reasons for going ahead: historical use it calls documented and quantified, lot-specific certificates of analysis from FDA-registered facilities that it says were not before CDER, and a view that CDER's safety concerns were inferential or mechanistic rather than observed harm. BioXconomy reported on 4 November 2026 that none of the evidence the HHS document refers to had been provided as of publication. Comments on docket HHS-OASH-2026-0496 close at 11:59 PM Eastern on 13 November 2026. The policy is not an FDA approval.
For research-community awareness only. Not legal advice.
